JAMDA
Volume 7, Issue 4 , Pages 234-240 , May 2006

The Application of Evidence-Based Principles of Care in Older Persons (Issue 3): Management of Diabetes Mellitus

  • Barbara J. Zarowitz, PharmD, FCCP, BCPS, CGP

      Affiliations

    • Omnicare, Inc, Livonia, MI
    • College of Pharmacy and Allied Health Sciences, Wayne State University, Detroit, MI
    • Corresponding Author InformationAddress correspondence to Barbara J. Zarowitz, PharmD, FCCP, BCPS, CGP, Omnicare, Inc., 13975 Farmington Road, Livonia, MI 48150
    • ,
  • Eric G. Tangalos, MD, FACP, AGSF, CMD

      Affiliations

    • Robert and Arlene Kogod Program on Aging, Mayo Clinic, Rochester, MN
    • ,
  • Kelly Hollenack, PharmD, CGP, FASCP

      Affiliations

    • Omnicare, Inc, Livonia, MI
    • ,
  • Terry O’Shea, PharmD, CGP, FASCP

      Affiliations

    • Omnicare, Inc, Livonia, MI

References 

  1. Prevalence of diabetes in 500,000 residents of long-term care facilities in the United States. Proprietary administrative data . Omnicare, Inc; 2004;
  2. Haines ST . The diabetes epidemic (Can we stop the spread?) . Pharmacother . 2003;23:1227–1231
  3. National Diabetes Information Clearing House. National Diabetes Statistics. NIH Publication No. 06-3892 November 2005.
  4. Diabetes in America. National Diabetes Data Group, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995. NIH Publication No. 95-1468.
  5. Gregg EW , Mangione CM , Cauley JA , et al.   Diabetes and incidence of functional disability in older women . Diabetes Care . 2002;25:61–67
  6. Travis SS , Buchanan RJ , Wang S , Kim MS . Analyses of nursing home residents with diabetes at admission . J Am Med Dir Assoc . 2004;4:320–327
  7. Gilmer TP , O’Connor PJ , Rush WJ , et al.   Predictors of health care costs in adults with diabetes . Diabetes Care . 2005;28:59–64
  8. Franse LV , Di Bari M , Shorr RI , et al.   Type 2 diabetes in older well-functioning people: Who is undiagnosed? Data from the Health, Aging, and Body Composition Study . Diabetes Care . 2001;24:2065–2070
  9. National Committee for Quality Assurance . State of Heath Care Quality . Washington, DC: National Committee for Quality Assurance; 2004;
  10. Smith NL , Savage PJ , Heckbert SR , et al.   Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus (The Cardiovascular Health Study) . J Am Geriatr Soc . 2002;50:416–423
  11. American Diabetes Association . Standards of medical care in diabetes . Diabetes Care . 2005;28(Suppl 1):S4–S79
  12. American Geriatrics Society . Guidelines for improving the care of the older person with diabetes mellitus . J Am Geriatr Soc . 2003;51(Suppl 1):S265–S280
  13. American Medical Directors Association . Managing Diabetes in the Long-Term Care Setting (Clinical Practice Guideline) . Columbia, MD: American Medical Directors Association; 2002;
  14. Zarowitz BJ , Stefanacci R , Hollenack KO , Shea T . The application of evidence-based principles of care in older persons (Issue 1) (Osteoporosis) . J Am Med Dir Assoc . 2006;7:102–108
  15. Davis S , Alonso MD . Hypoglycemia as a barrier to glycemic control . J Diabetes Complications . 2004;18:60–68
  16. UK Prospective Diabetes Study Group . Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) . Lancet . 1998;332:837–853
  17. Anonymous The Diabetes Control and Complications Trial Research Group . Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial . JAMA . 1996;276:1409–1415
  18. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus . N Engl J Med . 1993;329:977–986
  19. Lewis EJ , Hunsicker LG , Clarke WR , et al.   Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . N Engl J Med . 2001;345:851–860
  20. Parving HH , Lehnert H , Brochner-Mortensen J , et al.   The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes . N Engl J Med . 2001;345:870–878
  21. Brenner BM , Cooper ME , de Zeeuw D , et al.   Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy . N Engl J Med . 2001;345:861–869
  22. National Heart, Lung and Blood Institute National Institute of Health US Department of Health and Human Services . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VII) . 2005; August 2004. Available at: www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.htm. Accessed July 17
  23. Colhoun HM , Betteridge DJ , Durrington PN , et al.   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) (Multicenter randomised placebo-controlled trial) . Lancet . 2004;364:685–696
  24. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals (A randomised, placebo-controlled trial) . Lancet . 2002;360(9326):7–22
  25. Grundy SM , Cleeman JI , Merz NB , et al.   Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines . Circulation . 2004;110:227–239
  26. Ramlo-Halsted BA , Edelman SV . The natural history of type 2 diabetes (Practical points to consider in developing prevention and treatment strategies) . Clinical Diabetes . 2000;18:80–85
  27. Kirplchnikov D , McFarlane SI , Sowers JR . Metformin (An update) . Ann Intern Med . 2002;137:25–33
  28. DeFronzo R . Pharmacologic therapy for Type 2 diabetes . Ann Intern Med . 1999;17:281–303
  29. Nesto RW , Bell D , Bonow RO , et al.   Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association . Diabetes Care . 2004;27:256–263
  30. Hay LC , Wilmshurst EG , Fulcher G . Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus (The results of continuous glucose monitoring) . Diabetes Technol Therap . 2003;5:19–26
  31. Hollander PA , Levy P , Fineman MS , et al.   Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes (A 1-year randomized, controlled trial) . Diabetes Care . 2003;26:784–790
  32. Whitehouse F , Kruger DR , Fineman M , et al.   A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes . Diabetes Care . 2002;25:724–730
  33. DeFronzo RA , Ratner RE , Han J , Kim DD , Fineman MS , Baron AD . Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes . Diabetes Care . 2005;28:1092–1100
  34. Kendall DM , Riddle MC , Rosenstock J , et al.   Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea . Diabetes Care . 2005;28:1083–1091
  35. Carroll MF , Gutierrez A , Castro M , Tsewang D , Schade DS . Targeting postprandial hyperglycemia (A comparative study of insulinotropic agents in type 2 diabetes) . J Clin Endocrinol Metab . 2003;88:5248–5254
  36. Del Prato S , Heine RJ , Keilson L , Guitard C , Shen SG , Emmons RP . Treatment of patients over 64 years of age with type 2 diabetes. Experience from nateglinide pooled database retrospective analysis . Diabetes Care . 2003;26:2075–2080
  37. Yki-Jarvinen H , Dressler A , Ziemen M . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes . Diabetes Care . 2000;23:1130–1136
  38. Riddle M , Rosenstock J , Gerich J . The treat-to-target trial (Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients) . Diabetes Care . 2003;26:3080–3086

PII: S1525-8610(06)00003-X

doi: 10.1016/j.jamda.2006.01.002

JAMDA
Volume 7, Issue 4 , Pages 234-240 , May 2006

Article Tools

* Image Usage & Resolution